{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:09:56Z","timestamp":1783944596956,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clgc.2026.102596","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T23:35:09Z","timestamp":1780961709000},"page":"102596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating Tumor DNA After Radical Cystectomy as a Marker of Minimal Residual Disease in Muscle-Invasive Bladder Cancer: A Literature Review"],"prefix":"10.1016","volume":"24","author":[{"given":"Patricia","family":"Rodr\u00edguez-Parras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3993-3911","authenticated-orcid":false,"given":"Miguel","family":"\u00c1ngel Arrabal-Polo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Arrabal-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.clgc.2026.102596_bib0001","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102596_bib0002","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.euo.2024.03.002","article-title":"Longitudinal tumor-informed circulating tumor DNA status predicts disease upstaging and poor prognosis for patients undergoing radical cystectomy","volume":"7","author":"Ben-David","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102596_bib0003","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.euo.2024.07.001","article-title":"Association of tumor-informed circulating tumor DNA detectability before and after radical cystectomy with disease-free survival in patients with bladder cancer","volume":"8","author":"Sfakianos","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102596_bib0004","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/bju.16556","article-title":"Undetectable pre-radical cystectomy circulating tumour DNA status predicts improved oncological outcomes","volume":"135","author":"Ben-David","year":"2025","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.clgc.2026.102596_bib0005","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.eururo.2017.09.011","article-title":"Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis","volume":"73","author":"Birkenkamp-Demtr\u00f6der","year":"2018","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102596_bib0006","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.euf.2025.06.018","article-title":"In patients with muscle-invasive bladder cancer undergoing radical cystectomy, dynamics of circulating tumor DNA following cystectomy: association with patient outcomes","volume":"11","author":"Tasios","year":"2025","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.clgc.2026.102596_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2024.08.006","article-title":"The prognostic significance of circulating tumor DNA in patients with positive lymph node disease after robotic-assisted radical cystectomy: a contemporary analysis","volume":"43","author":"Ben-David","year":"2025","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102596_bib0008","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.eururo.2024.05.014","article-title":"Whole-genome mutational analysis for tumor-informed detection of circulating tumor DNA in patients with urothelial carcinoma","volume":"86","author":"Nordentoft","year":"2024","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.clgc.2026.102596_bib0009","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2217\/fon-2022-0868","article-title":"IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery","volume":"19","author":"Jackson-Spence","year":"2023","journal-title":"Future Oncol"},{"issue":"19","key":"10.1016\/j.clgc.2026.102596_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911732","article-title":"Cell-free DNA as a prognostic biomarker for monitoring muscle-invasive bladder cancer","volume":"23","author":"Carrasco","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"23","key":"10.1016\/j.clgc.2026.102596_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242316578","article-title":"Tumor-agnostic circulating tumor DNA testing for monitoring muscle-invasive bladder cancer","volume":"24","author":"Carrasco","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.clgc.2026.102596_bib0012","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s44276-025-00143-4","article-title":"Monitoring circulating tumor DNA by recurrent hotspot mutations in bladder cancer","volume":"3","author":"Tsukahara","year":"2025","journal-title":"BJC Rep"},{"issue":"2","key":"10.1016\/j.clgc.2026.102596_bib0013","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","article-title":"Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"85","author":"Powles","year":"2024","journal-title":"Eur Urol"},{"issue":"24","key":"10.1016\/j.clgc.2026.102596_bib0014","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"IMvigor011 Investigators. CtDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102596_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.12.018","article-title":"ctDNA-guided immunotherapy following radical cystectomy for muscle-invasive bladder cancer: results from the TOMBOLA trial","author":"Dyrskj\u00f8t","year":"2026","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102596_bib0016","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.euo.2025.04.027","article-title":"Bladder cancer with undetectable circulating tumor DNA after radical cystectomy may be amenable to a less intense imaging surveillance protocol: a diagnostic accuracy study","volume":"8","author":"Eraky","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"7","key":"10.1016\/j.clgc.2026.102596_bib0017","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11934-015-0520-z","article-title":"Do circulating tumor cells have a role in deciding on adjuvant chemotherapy after radical cystectomy?","volume":"16","author":"Soave","year":"2015","journal-title":"Curr Urol Rep"},{"issue":"11","key":"10.1016\/j.clgc.2026.102596_bib0018","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1186\/2047-783X-14-11-487","article-title":"Perioperative search for circulating tumor cells in patients undergoing radical cystectomy for bladder cancer","volume":"14","author":"Karl","year":"2009","journal-title":"Eur J Med Res"},{"issue":"4","key":"10.1016\/j.clgc.2026.102596_bib0019","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.clgc.2016.11.005","article-title":"Detection and clinical significance of circulating tumor cells in patients undergoing radical cystectomy for urothelial bladder cancer","volume":"15","author":"Pagliarulo","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2026.102596_bib0020","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.juro.2015.02.2951","article-title":"Circulating tumor cells as potential biomarkers in bladder cancer","volume":"194","author":"Alva","year":"2015","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102596_bib0021","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3390\/diagnostics13061032","article-title":"Circulating tumor cells predict response of neoadjuvant chemotherapy in patients with bladder cancer: a preliminary study","volume":"13","author":"Jhuo","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"2","key":"10.1016\/j.clgc.2026.102596_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100416","article-title":"Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer","volume":"7","author":"Beije","year":"2022","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.clgc.2026.102596_bib0023","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.eururo.2012.01.017","article-title":"Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study","volume":"61","author":"Rink","year":"2012","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102596_bib0024","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s13402-023-00785-x","article-title":"In vivo detection demonstrates circulating tumor cell reduction instead of baseline number has prognostic value in bladder cancer patients receiving neoadjuvant chemotherapy","volume":"46","author":"Jin","year":"2023","journal-title":"Cell Oncol (Dordr)"},{"issue":"10","key":"10.1016\/j.clgc.2026.102596_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2017.05.021","article-title":"Circulating tumor cells in patients with advanced urothelial carcinoma of the bladder: association with tumor stage, lymph node metastases, FDG-PET findings, and survival","volume":"35","author":"Abrahamsson","year":"2017","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102596_bib0026","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3390\/biomedicines12040921","article-title":"Circulating tumour DNA and its prognostic role in management of muscle invasive bladder cancer: a narrative review of the literature","volume":"12","author":"Kapriniotis","year":"2024","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/j.clgc.2026.102596_bib0027","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/14737140.2025.2512036","article-title":"The use of ctDNA for muscle-invasive bladder cancer before and after radical cystectomy","volume":"25","author":"Manolitsis","year":"2025","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:19:01Z","timestamp":1783941541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1558767326000960"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102596","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating Tumor DNA After Radical Cystectomy as a Marker of Minimal Residual Disease in Muscle-Invasive Bladder Cancer: A Literature Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102596","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102596"}}